Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20869031 | 0.86 | EGFR (0.44) | EGFRNPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL30101760 | 0.86 | EGFR (0.44) | EGFRNPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL248758 | 0.84 | GAA (0.48) | EGFRSMN1; SMN2ALDH1A1CYP3A4HIF1A | |
| SCHEMBL31047861 | 0.83 | AAK1 (0.48) | NPC1RECQLRAB9ASMN1; SMN2AAK1 | |
| SCHEMBL9971024 | 0.83 | AAK1 (0.48) | NPC1RECQLRAB9ASMN1; SMN2AAK1 | |
| SCHEMBL15050032 | 0.82 | EGFR (0.44) | EGFRANO1 | |
| SCHEMBL14564600 | 0.80 | TSHR (0.44) | EGFRNPC1RAB9AHIF1ACA12 | |
| SCHEMBL9971059 | 0.80 | GAA (0.51) | NPC1RECQLRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21847323 | 0.76 | NAMPT (0.40) | EGFRNPC1RAB9ACYP3A4GAA | |
| SCHEMBL19201249 | 0.75 | KDM4A (0.44) | NPC1RECQLRAB9ASMN1; SMN2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797893-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-11-05 | — | — | EP | claimed |
| WO-2013101598-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| EP-2797893-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2797893-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9522890-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522890-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2016-03-10 | — | — | US | disclosed |
| EP-2966064-A1 | PYRAZOLE-3-CARBOXYLIC ACID COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966064-A1 | PYRAZOLE-3-CARBOXYLIC ACID COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9090566-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20090239845-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | CONWAY ELIZABETH ANN | 2009-09-24 | — | — | US | disclosed |
| EP-1675832-B1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1675832-B1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1874303-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| WO-2006114313-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| EP-1675832-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005040128-A1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239845-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | PTGER1, PTGDR, PTGIR | EGFR 1217/4885NPC1 3127/4885RECQL 1566/4885 |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | PTGER4, PTGER1, GRK4 | EGFR 82/4885NPC1 3468/4885RECQL 3399/4885 |
| US-20070060596-A1 | Heterocyclyl compounds | F9, F12, CYP2C9 | EGFR 1573/4885NPC1 1605/4885RECQL 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.